Summarily, the chimeric vaccine candidate (designated TB-MEVA−1) comprised 683 amino acid residues, which included 27 M. tuberculosis predicted epitopes, the incorporated immune potentiators (TLR4 agonist, TAT, and PADRE), and diverse linkers (Figure 1). This evidence concerns the gene TLR4 and tuberculosis.